apg115
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2019 (NCT03781986)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2- Mol. weight
- 642.6 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4091801 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03781986 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2019 | Ascentage Pharma Group Inc., University of Michigan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascentage Pharma Group Inc. | For profit | 1 | 1 | 1 | 2019 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1